Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)
Year: 2013
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, University of California, Los Angeles, Hackensack University Medical Center, Abramson Cancer Center, University of Pennsylvania, Hôtel-Dieu de Paris, University of Bologna, Johns Hopkins University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1025733650